CRB licenses biodrug delivery protein screening tech

By Gareth Macdonald contact

- Last updated on GMT

CRB licneses cell penetration delivery screening tech
CRB licneses cell penetration delivery screening tech

Related tags: Protein

Cambridge Research Biochemicals (CRB) has licensed rights to a system that – it claims – will let biopharmas identify the best delivery peptides more quickly.

The technology – which was developed by scientists at the UK Medical Research Council’s Laboratory of Molecular Biology (MRC-LMB) – allows CRB to combine a biopharmas customers’ biomolecule with many different cell penetration peptides simultaneously to accelerate the selection process as spokesman Laurent Caron explained.

There isn’t a universally successful carrier and often researchers have to select one that works for a particular cargo and a particular cell type. We offer researchers a screening tool to identify successful carriers for their application saving them time and money​.”

He told that screening is necessary because while a lot of research has been done the mechanism by which peptide enter cells is poorly understood, making it difficult to identify the molecule with the best characteristics for drug delivery.

There are unresolved questions regarding the uptake mechanism of cell penetrating peptides and different pathways have been suggested. Direct penetration is a possible explanation, the carrier CPP forming a pore or a micelle by interaction with the cell membrane.”

UK-headquartered CRB plans to begin offering the technology as a contract service to scientists working in academia and at biotech and pharmaceutical companies for research purposes from October as commercial director Emily Humphrys explained.

"We are really pleased to be able to provide a long-awaited service for the selection of the most appropriate cell-penetrating peptide for delivery of drugs to both academic researchers and industry

Mike Gait, from the MRC, was similarly upbeat, adding that: "We are very excited that CRB has taken on our new method and will open it up to a wider number of researchers and to industry, ultimately enabling the development of new treatments."

Related topics: Bio Developments, Bio-Outsourcing

Related news

Show more

Related products

show more

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

The Reagents Behind Much of Molecular Biology

The Reagents Behind Much of Molecular Biology

Thermo Fisher Scientific | 25-Jul-2022 | Case Study

The ability to amplify, modify and fabricate DNA is fundamental to modern molecular biology. Why do so many researchers take their constituent parts for...

Microsampling in Early Phase Drug Development

Microsampling in Early Phase Drug Development

Altasciences | 10-May-2022 | Technical / White Paper

Microsampling significantly lessens the volume of blood and plasma/serum that is collected and analyzed to determine circulating concentrations of therapeutic...

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Related suppliers

Follow us


View more